Franklin Lakes, N.J.-based Beckton Dickinson & Co. (BD) has agreed to buy Carmel Pharma AB for an undisclosed amount paid in cash.
Carmel, which is located in Gothenburg, Sweden, manufacturers closed drug transfer systems for handling medications. Carmel’s proprietary PhaSeal system is a unique safety solution designed to protect healthcare workers, patients, the drug and hospitals from litigation and waste.
PhaSeal’s double-membrane technology and a unique pressure-equalizing function ensures an air tight, leak proof solution throughout the entire preparation, administration and waste disposal chain.
“Carmel Pharma has achieved excellent growth over the last five years, driven by an exceptional product, a first class team of employees and very supportive shareholders.” Dan Pitulia, CEO of Carmel, said. “I believe BD will be an excellent owner and it has all the capabilities to accelerate Carmel Pharma’s next phase of growth. We will benefit hugely from BD’s access to new customers and from the fact that PhaSeal is complementary to BD’s existing product range.”